This prompted developing a series of cell lines using CRISPR/Cas9 to introduce various clinically relevant point mutations associated with acquired BRAF inhibitor resistance into a BRAF V600E melanoma cell line ([65]; www.atcc.org). The gene discussed is BRAF; the disease is melanoma.